Cancer Therapy : Preclinical Dual Blockade of HER 2 inHER 2-Overexpressing TumorCells Does Not Completely Eliminate HER 3 Function

@inproceedings{Garrett2013CancerT,
  title={Cancer Therapy : Preclinical Dual Blockade of HER 2 inHER 2-Overexpressing TumorCells Does Not Completely Eliminate HER 3 Function},
  author={Joan T. Garrett and Cammie R. Sutton and Maria G Kuba and Rebecca S. Cook and Carlos L. Arteaga},
  year={2013}
}
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approach. Inhibition of HER2 and downstream phosphoinositide 3-kinase (PI3K)/AKT causes a transcriptional and… CONTINUE READING